Pharmacist HPV Vaccination Resources

Pharmacist HPV Vaccination Resources

It’s not too late: Protect your adult patients against certain HPV-related cancers and diseases

Why adult HPV vaccination matters

  • Many adults may remain at risk: Although new HPV infections are most common in adolescence and young adulthood, adults
    can still acquire new infections, especially if they have new sexual partners1,2
  • GARDASIL® 9 (Human Papillomavirus 9 valent Vaccine) (Recombinant, adsorbed) is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases: premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types, and genital warts (Condyloma acuminata) caused by specific HPV types3
  • Gardasil 9 has been studied in males 9 to 26 years of age and females 9 to 45 years of age3
  • Protection even after exposure: If a patient has already been infected with one HPV type, Gardasil 9 can help protect them
    against other HPV types they haven’t encountered3,4

Do you want to learn more about how HPV vaccination can benefit your eligible patients?

New Healthcare Professional eLearning

Understand what HPV is, your role in vaccination and why you should consider vaccinating your eligible patients. Feel equipped to start a conversation today.

Access free eLearning
Pharmacist looking at computer screen.

Your role as a healthcare professional is crucial

Your role is of critical importance in improving HPV vaccination uptake – here’s how you can make a difference5,6:

  • A recommendation from a healthcare provider may affirm patients’ perceptions of the value of vaccination7
  • The decision to receive the HPV vaccine is governed by the decisions of policy makers, healthcare professionals and parents8

Pharmacist discussion guide

This guide can help support you in identifying eligible patients, with tips on starting conversations with your patients including FAQs

Start an impactful conversation with patients about HPV vaccination
Access Discussion Guide

Take action today

  • Identify eligible patients by leveraging key touchpoints – such as consultations for sexual health, requests for contraception, or cervical screening tests – as opportunities to initiate a conversation about HPV vaccination3
  • Start the conversation: Explain the benefits of vaccination clearly and confidently and let your patients know that the HPV vaccine is offered by the NHS to children aged 12-13, as well as girls under 25 and boys born after 1 September 2006 who missed having the vaccine at school3
  • Address concerns: Provide reassurance about safety and efficacy3
  • Use available resources: MSD Connect offers patient materials, discussion guides and educational resources to support your
    clinical practice

HPV vaccination leaflet

This detailed HPV vaccination leaflet offers additional information for patients who have already shown interest in HPV vaccination

Information for those considering HPV vaccination
Access HPV Vaccination Leaflet

How to order GARDASIL 9 vaccine?

MSD Medicines and Vaccines can be ordered from:
Alliance Healthcare Customer Services 
Telephone: 0330 100 0448
Email: customerservice@alliance-healthcare.co.uk

Customer service

MSD UK customer services
(9am-5pm, Mon-Fri)
Telephone: 0208 1548001
(Out of normal working hours, during public holidays and weekends, please contact our UK switchboard on 0208 1548000)

We’re here to support you every step of the HPV vaccination journey

Relevant resources – when you need them most

Sign up to receive relevant resources and valuable updates when you need them most – helping you address hesitancy and build confidence throughout the journey. Some of these resources may be promotional in nature.

You can unsubscribe at any time.

Yes, I want to receive HPV resources

References

  1. Bruni L, Albero G, Rowley J et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023 Sep;11(9):e1345-e1362.
  2. Bruni L et al. ICO/IARC Information Centre on HPV and Cancer. Human Papillomavirus and Related Diseases in United Kingdom of Great Britain and Northern Ireland. Summary Report; 10 March 2023. Accessed October 2025. Available at: https://hpvcentre.net/statistics/reports/GBR.pdf?t=1754915544609.
  3. GARDASIL 9 Summary of Product Characteristics.
  4. Cuschieri KS, Cubie HA, Whitley MW et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004;57:68-72.
  5. Overview | Community pharmacies: promoting health and wellbeing | Guidance | NICE. Accessed October 2025. https://www.nice.org.uk/guidance/ng102.
  6. World Health Organization (WHO). HPV vaccine communication. Special considerations for a unique vaccine: 2016 update. Accessed October 2025. Available at: https://iris.who.int/server/api/core/bitstreams/48cf689f-4dbc-40ca-9a08-8791e313047d/content.
  7. Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing Vaccination: Putting Psychological Science Into Action. Psychol Sci Public Interest. 2017;18(3):149-207. doi:10.1177/1529100618760521.
  8. Ferrer HB, Trotter C, Hickman M et al. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health 14. 2014;700. Available at: https://doi.org/10.1186/1471-2458-14-700.

Supporting documentation

GARDASIL® 9 (Human Papillomavirus 9 valent Vaccine) (Recombinant, adsorbed)
Prescribing Information [External link]

By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-GSL-00851 | Date of preparation: November 2025

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.
Registered in England No. 233687 © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

GB-NON-12769 | Date of Preparation: March 2026

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).